Single Dose of Sputnik V Vaccine Triggers Strong Response

94% of the participants developed IgG antibodies against the virus 3 weeks after administration.

A recent study conducted by investigators from the Fundación Instituto Leloir-CONICET in Argentina has discovered that a single dose of the Russian developed Sputnik V vaccine elicits a significant antibody response against SARS-CoV-2.

Results from the study were published in the journal Cell Reports Medicine

“Massive vaccination offers great promise for halting the global COVID-19 pandemic. However, limited supply and uneven vaccine distribution create an urgent need to optimize vaccination strategies,” the authors wrote. “The data presented provide information for guiding public health decisions in light of the current global health emergency.”

For the study, the team of investigators compared the effects of 1 and 2 doses of the Sputnik V vaccine in 288 participants who worked in the healthcare field.

Findings from the study demonstrated that 3 weeks after the second dose, all of the participants with no prior infection generated virus-specific immunoglobulin G (IgG) antibodies. Within 3 weeks of administration, 94% of the participants developed IgG antibodies and 90% showed evidence of neutralizing antibodies.

Additional findings showed that IgG and neutralizing antibody levels in previously infected participants were significantly higher after one dose than those in fully vaccinated volunteers with no history of infection.

A second dose of the vaccine did not increase the production of neutralizing antibodies in previously infected volunteers.

"Due to limited vaccine supply and uneven vaccine distribution in many regions of the world, health authorities urgently need data on the immune response to vaccines to optimize vaccination strategies," Andrea Gamarnik, senior author on the study said. "The peer-reviewed data we present provide information for guiding public health decisions in light of the current global health emergency."